The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

MultiPark Debate – Aducanumab (YES/NO)

Ruben Smith presenting his arguments during the debate. Photo.

What is the best approach for treating Alzheimer's disease? Aducanumab is an amyloid beta-directed monoclonal antibody that targets the aggregated forms of amyloid beta found in the brains of people with Alzheimer's disease. In May, Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith entertained young MultiParkers by debating the pros and cons of using it.

Last summer, Aducanumab was approved by the FDA as a treatment for Alzheimer's disease. The young MultiParker's working group arranged a scientific debate where Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith, two of MultiPark's senior researchers, discussed the topic. 

Watch the recorded version of the debate below. 

 

Profile photo of Niklas Mattsson-Carlgren

Niklas Mattsson-Carlgren

Senior Lecturer

niklas [dot] mattsson-carlgren [at] med [dot] lu [dot] se

Link to Niklas Mattsson-Carlgren's profile in the LU Research Portal

Twitter: @NiklasMattsson4

Profile photo of Ruben Smith
Photo: Karin Enell Smith

Ruben Smith

Physician and Associate Professor in Neurology

ruben [dot] smith [at] med [dot] lu [dot] se 

Link to Ruben Smith in Lund University research portal

Twitter:@ErikRubenSmith